These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38467912)

  • 1. Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study.
    Bessette L; Chan J; Chow A; Lisnevskaia L; Richard N; Fournier PA; Liazoghli D; Girard T; Haaland D
    Rheumatol Ther; 2024 Jun; 11(3):563-582. PubMed ID: 38467912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
    Baker JF; Zueger P; Ali M; Bennett D; Yu M; Munoz Maldonado Y; McLean RR
    Rheumatol Ther; 2024 Apr; 11(2):363-380. PubMed ID: 38345715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study.
    Kivitz A; Wells AF; Vargas JI; Baraf HSB; Rischmueller M; Klaff J; Khan N; Li Y; Carter K; Friedman A; Durez P
    Rheumatol Ther; 2023 Aug; 10(4):901-915. PubMed ID: 37199884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.
    Werner SG; Baraliakos X; Reckert S; Bohl-Bühler M; Laliberté MC; Girard T; Jeromin K; Baschuk N; Fritz B; Bessette L; Hueber AJ
    Rheumatol Ther; 2023 Dec; 10(6):1503-1518. PubMed ID: 37695506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
    Haraoui B; Khraishi M; Choquette D; Lisnevskaia L; Teo M; Kinch C; Galos C; Roy P; Gruben D; Woolcott JC; Vaillancourt J; Sampalis JS; Keystone EC;
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):240-251. PubMed ID: 35678771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
    Harrold LR; Zueger P; Nowell WB; Blachley T; Schrader A; Lakin PR; Curtis D; Stradford L; Venkatachalam S; Tundia N; Patel PA
    Rheumatol Ther; 2023 Dec; 10(6):1519-1533. PubMed ID: 37728861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
    Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
    Conaghan P; Cohen S; Burmester G; Mysler E; Nash P; Tanaka Y; Rigby W; Patel J; Shaw T; Betts KA; Patel P; Liu J; Sun R; Fleischmann R
    Rheumatol Ther; 2022 Feb; 9(1):191-206. PubMed ID: 34816388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.
    Conaghan PG; Pavelka K; Hsieh SC; Bonnington TL; Kent TC; Marchbank K; Edwards CJ
    Rheumatol Adv Pract; 2023; 7(1):rkad017. PubMed ID: 36794283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
    Cai W; Tong R; Sun Y; Yao Y; Zhang J
    Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
    Witte T; Kiltz U; Haas F; Riechers E; Prothmann U; Adolf D; Holland C; Rössler A; Soppa U; Fritz B; Götz K; Krüger K;
    Clin Exp Rheumatol; 2024 Mar; 42(3):726-735. PubMed ID: 37976112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
    Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
    Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
    Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.